Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 3.0.1-SNAPSHOT built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions
Generated Narrative: DiagnosticReport PGxGenomicReportEMERGE
Subject | Adam B. Everyman Male, DoB: 1951-01-20 ( Medical Record Number: m123 (use: usual, )) |
When For | 2020-01-01 00:00:00-0500 |
Reported | 2020-01-01 00:00:00-0500 |
Performer | Organization some lab |
Report Details
Code | Value | Flags | Note | When For |
Therapeutic Implication | Final | 2019-04-01 | ||
Therapeutic Implication | Final | 2019-04-01 | ||
Therapeutic Implication | Final | 2019-04-01 | ||
Therapeutic Implication | Final | 2019-04-01 | ||
Therapeutic Implication | Final | 2019-04-01 | ||
Therapeutic Implication | Final | 2019-04-01 | ||
Genotype display name | CYP2C19*2/*2 | Final | 2019-04-01 | |
Genotype display name | VKORC1 rs9923231 C/T | Final | 2019-04-01 | |
Genotype display name | CYP2C9*1/*1 | Final | 2019-04-01 | |
Genetic variant assessment | Present | Final | 2020-01-01 | |
Genetic variant assessment | Present | Final | 2019-04-01 | |
Genetic variant assessment | Present | Final | 2019-04-01 | |
Genetic variant assessment | Present | Final | 2019-04-01 | |
Genetic variant assessment | Present | Final | 2019-04-01 | |
Genetic variant assessment | Present | Final | 2019-04-01 | |
Genetic variant assessment | Present | Final | 2019-04-01 | |
Genetic variant assessment | Present | Final | 2019-04-01 | |
Genetic variant assessment | Present | Final | This variant was confirmed with SANGER sequencing | 2019-04-01 |
Genetic variant assessment | Present | Final | This variant was confirmed with SANGER sequencing | 2019-04-01 |
Genetic variant assessment | Present | Final | This variant was confirmed with SANGER sequencing | 2019-04-01 |
Based on the genotype result, this patient is predicted to have a CYP2C19 poor metabolizer phenotype. This genotype information can be used by patients and clinicians as part of the shared decision-making process for several drugs metabolized by CYP2C19 including clopidogrel, voriconazole, amitriptyline, citalopram and escitalopram.
Coded Conclusions: